{
    "data": [
        {
            "id": "4557323",
            "type": "article",
            "attributes": {
                "publishOn": "2022-11-13T23:37:27-05:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1351786569/image_1351786569.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "ResMed Inc. Lets Investors Breath Easy",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "62873",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "420075",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "3545",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4557323-resmed-inc-lets-investors-breath-easy"
            }
        },
        {
            "id": "4557286",
            "type": "article",
            "attributes": {
                "publishOn": "2022-11-13T19:42:49-05:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1341970685/image_1341970685.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "ResMed: Strong Earnings Growth Supports The High Valuation, Unclear Technical Trends",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106553",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "420098",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "3545",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4557286-resmed-stock-strong-earnings-growth-supports-high-valuation-unclear-technical-trends"
            }
        },
        {
            "id": "4537699",
            "type": "article",
            "attributes": {
                "publishOn": "2022-08-29T13:00:24-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1314949311/image_1314949311.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "ResMed: Long-Term Thesis Remains Unchanged, Rate Buy For Compelling Value",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105793",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "406520",
                            "type": "sentiment"
                        },
                        {
                            "id": "406521",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "3545",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4537699-resmed-long-term-thesis-remains-unchanged-rate-buy-for-compelling-value"
            }
        },
        {
            "id": "4537677",
            "type": "article",
            "attributes": {
                "publishOn": "2022-08-29T11:36:04-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1353883792/image_1353883792.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "ResMed: Further Downside Is Warranted",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "69675",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "406325",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "3545",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4537677-resmed-further-downside-warranted"
            }
        },
        {
            "id": "4516859",
            "type": "article",
            "attributes": {
                "publishOn": "2022-06-07T10:31:33-04:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1309171514/image_1309171514.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "ResMed: Near-Term Upside From Philips Withdrawal, Seeking $35 Per Share Return Objective",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105793",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "377349",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "3545",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4516859-resmed-near-term-upside-from-philips-withdrawal-seeking-35-per-share-return-objective"
            }
        },
        {
            "id": "4492469",
            "type": "article",
            "attributes": {
                "publishOn": "2022-03-03T05:55:52-05:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/184877956/image_184877956.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "ResMed: Fantastic Firm But Fantastically Overpriced",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "69675",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "363970",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "3545",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4492469-resmed-stock-fantastically-overpriced"
            }
        },
        {
            "id": "4485471",
            "type": "article",
            "attributes": {
                "publishOn": "2022-02-09T09:45:09-05:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "ResMed CEO Mick Farrell - Sleep Apnea More Fatal Than Smoking",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106115",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "3545",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4485471-resmed-ceo-mick-farrell-sleep-apnea-more-fatal-than-smoking"
            }
        }
    ]
}